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Background 
• Early breast cancer patients with unfavourable 
prognostic factors are often treated with both 
chemotherapy (CT) and radiotherapy (RT).  
• Delay in the start of RT or CT may result in increased 
risk of locoregional and/or distant recurrence. 
• The optimal sequence of RT and CT is subject for 
debate.  
 
 
 
Background 
• Concurrent  administration of RT and CT might 
improve locoregional control 
• Concurrent CT and RT is not advised in the 
Netherlands because of the excess risk of treatment-
related side effects  
• Studies until now are often preformed with selected 
(small) populations 
• Sequencing in the Netherlands was arbitrary and not 
according to national guidelines 
 
 
 
Aim of the study 
Determine the effect of RT and CT sequence on overall 
survival (OS) and recurrence-free survival (RFS) using a 
large dataset from a population-based cancer registry. 
 
Materials & methods  
• Cases selected from the Netherlands Cancer Registry 
• All primary breast cancers diagnosed 1999-2008 
 
• Cox and competing risk regression was used to 
compare OS and RFS in two treatment groups  
- RT first 
- CT first 
• adjustment for important prognostic variables 
 
Selection of cases 
• 131,122 primary breast cancers in 1999-2008 
- Exclusion: Tis, TX, T4, M1, second breast cancers, 
no surgery, neo-adjuvant treatment 
• 93,399 T1-3M0 treated with surgery  
- Exclusion: no combination of RT and CT 
• 22,045 primary breast cancer patients received both 
CT and RT (after surgery) 
- 9,977 (45%) received RT first 
- 2,068 (55%) received CT first.  
- during a total of 112,872 patient years of follow-up 
(median 57 months), 3,075 patients died.  
Distributions of the treatment options 
Ratio RT/CT first over the years 
Results 
Overall survival (OS) 
Overall survival (OS) 
• adjustments for age, stage, number of positive lymph 
nodes, histological grade and administration of hormone 
therapy: 
- no survival difference for CT first compared to RT first 
(hazard ratio (HR) 0.97; 95%CI 0.90-1.05; P=0.46).  
• Additional adjustment for hormone receptor status, HER2 
status and tumor diameter available for a subgroup of 
9,951 patients: 
- confirmation of these results (HR 0.96; 95%CI 0.79-
1.16; P=0.66).  
 
OS according to type of surgery 
OS according to nr of positive lymph nodes 
Disease-free survival (DFS) 
• In 6,582 patients data on recurrent disease were 
specifically documented (period 2003-2006) 
• 30,762 patient years of follow-up (median 61 months) 
• 1,259 patients experienced one or more recurrences 
 
Recurrence type documented in the 
recurrence cohort 
Disease-free survival (DFS) 
• No significant recurrence-free survival benefit was 
seen for either treatment sequence (HR 0.97; 95%CI 
0.86-1.10; P=0.64). 
 
RFS according to type of surgery 
RFS according to nr of positive lymph nodes 
Conclusion 
A large analysis of prospectively collected cancer 
registry data of primary breast cancer patients after a 
median follow-up of approximately 5 years 
 
 
The sequence of radio- and chemotherapy as practiced 
in routine clinical care did not affect overall-survival or 
recurrence-free survival  
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